CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for CERo Therapeutics Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CERo Therapeutics Holdings Inc
201 Haskins Way, Suite 230
Phone: (215) 731-9450p:215 731-9450 SOUTH SAN FRANCISCO, CA  94080  United States Ticker: CEROCERO
Business Summary
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
(Source: 10KSB40)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Interim Chairman of the Board and Chief Executive Officer Christopher B.Ehrlich 53 9/30/2024 6/1/2021
Chief Financial Officer AndrewAlbert 43 10/1/2024 10/1/2024
Chief Development Officer KristenPierce 54 10/1/2024 10/1/2024
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
CERo Therapeutics, Inc. 201 Haskins Way South San Francisco CA United States

Business Names
Business Name
CERO
CERo Therapeutics, Inc.
PBAX
PBAXU

General Information
Number of Employees: 8 (As of 4/1/2024)
Outstanding Shares: 152,138,822 (As of 10/2/2024)
Shareholders: 1
Stock Exchange: NASD
Federal Tax Id: 871088814
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024